SONOSCAPE(SZ:300633) Xin Lang Cai Jing·2025-10-09 02:37Core Viewpoint - KAILI Medical's stock price has shown fluctuations, with a year-to-date increase of 15.02%, but a recent decline of 3.49% over the last five trading days, indicating potential volatility in the market [1] Financial Performance - For the first half of 2025, KAILI Medical reported a revenue of 964 million yuan, a year-on-year decrease of 4.78%, and a net profit attributable to shareholders of 47.03 million yuan, down 72.43% compared to the previous year [2] - Cumulative cash dividends since the A-share listing amount to 381 million yuan, with 258 million yuan distributed over the last three years [3] Shareholder Structure - As of June 30, 2025, the number of shareholders decreased by 1.46% to 14,300, while the average circulating shares per person increased by 1.48% to 30,244 shares [2] - Notable institutional shareholders include Huabao Zhongzheng Medical ETF and Guangfa Medical Health Stock A, with both increasing their holdings [3] Company Overview - KAILI Medical, established on September 27, 2002, and listed on April 6, 2017, specializes in the research, development, production, and sales of medical diagnostic and treatment equipment [1] - The company's main revenue sources are color ultrasound (58.07%) and endoscopes and related therapeutic instruments (40.90%) [1] Market Position - KAILI Medical operates within the pharmaceutical and biological industry, specifically in the medical device sector, and is involved in various concept sectors including medical devices and in vitro diagnostics [1]